Rising Tariffs Disrupt U.S. Supply of Traditional Chinese Medicine

Washington, D.C. – May 18, 2025 – The U.S. market for Traditional Chinese Medicine (TCM) is facing a severe crisis as new tariffs on Chinese imports threaten supply chains and affordability. Industry experts warn that the rising costs could cripple practitioners and patients who rely on herbal remedies and specialized treatments.

The tariffs, imposed as part of ongoing trade tensions, have significantly increased the price of key medicinal herbs and pharmaceutical ingredients sourced from China. Many TCM practitioners in the U.S. are struggling to maintain their businesses, with some reporting a 40% rise in costs for essential herbs like ginseng, astragalus, and goji berries.

According to trade analysts, the U.S. is heavily dependent on China for active pharmaceutical ingredients (APIs) used in both traditional and modern medicine. The restrictions could lead to shortages of critical medications, including pain relievers and anti-inflammatory drugs.

Industry leaders are urging policymakers to reconsider the tariffs, warning that the move could disrupt healthcare access for thousands of patients who rely on TCM treatments. Meanwhile, Chinese suppliers are exploring alternative markets, potentially shifting exports to Europe and Southeast Asia to offset losses.

As the situation unfolds, practitioners and patients alike are left wondering how they will adapt to the rising costs and potential shortages in the coming months.